[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fL90ehka0Rzpv9v0B1_DDM4ZCo1TJpIg3X9iNNxuvJ3g":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":85,"rows":92},"Centre for Addiction and Mental Health",[4],334,false,72,3,76378,25,219,[14,17,20,23,26,28,31,34],{"name":15,"count":16},"Schizophrenia",46,{"name":18,"count":19},"Major Depressive Disorder",35,{"name":21,"count":22},"Depression",28,{"name":24,"count":25},"Schizoaffective Disorder",18,{"name":27,"count":25},"Nicotine Dependence",{"name":29,"count":30},"Psychosis",13,{"name":32,"count":33},"Smoking Cessation",12,{"name":35,"count":36},"Tobacco Use Disorder",11,[38,43,48,53,57,62,67,71,76,80],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05515354","Smoking Cessation and Menstrual Cycle Phase","2026-04-30","Nicotine Replacement Therapy Agent",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06299319","Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD","2026-06","Psilocybin",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06512389","Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder","2026-06-30","Oral solution",{"nctId":54,"briefTitle":55,"date":56,"intervention":47},"NCT06041152","Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment","2026-07",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT03741478","Intranasal Insulin and Olanzapine Study in Healthy Volunteers","2026-07-30","OLANZapine 2.5 MG",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05333003","Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity","2026-08","Semaglutide",{"nctId":68,"briefTitle":69,"date":65,"intervention":70},"NCT02808533","Topiramate and Schizophrenia: Effects on Weight and Psychopathology","Topiramate",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06251635","Effects of Antipsychotics on Brain Insulin Action in Females","2026-08-01","Olanzapine 2.5Mg Oral",{"nctId":77,"briefTitle":78,"date":74,"intervention":79},"NCT05748990","Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia","Intranasal insulin",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06534047","Transcranial Magnetic Stimulation for Nicotine Dependence: An Effectiveness-Implementation Trial","2026-09-01","Nicotine replacement",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,139,176,204,225,243,274,292,314,357,386,437,494,516,537,569,587,643,672,702,720,738,759,777,795,815,848,881,899,917,935,953,979,1004,1027,1052,1077,1095,1117,1140,1164,1191,1225,1249,1279,1303,1327,1350,1375,1397,1420,1438,1462,1485,1507,1532,1556,1580,1603,1627,1652,1670,1688,1706,1728,1752,1777,1795,1820,1838,1865,1883,1901,1927,2039,2097,2139,2168,2200,2222,2244,2269,2296,2320,2338,2363,2381,2406,2428,2451,2475,2502,2520,2538,2556,2581,2604,2622,2646,2670,2693,2717,2735,2762,2787,2810,2834,2858,2881,2903,2925],{"intervention":94,"totalTrials":95,"cells":96},"Haloperidol",2,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":118,"PHASE4":120,"NA":137},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NCT02203786","D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement","COMPLETED",[88],"2015-06","2015-09","2009-09",60,[114],"Pathological Gambling",[94,116,117],"Fluphenazine","Dexedrine",{"trials":119,"activeCount":99},[],{"trials":121,"activeCount":136,"soonestReadout":127},[122],{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":128,"start":129,"enrollment":19,"conditions":130,"interventions":134},"NCT07109245","Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?","RECRUITING",[90],"2028-08","2028-12","2025-12-11",[131,132,133],"Brain Insulin Sensitivity","Healthy Controls","Cognition",[94,135],"Insulin Lispro",1,{"trials":138,"activeCount":99},[],{"intervention":140,"totalTrials":95,"cells":141},"Metformin",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":174},{"trials":143,"activeCount":99},[],{"trials":145,"activeCount":99},[],{"trials":147,"activeCount":99},[],{"trials":149,"activeCount":99},[],{"trials":151,"activeCount":136,"soonestReadout":166},[152,162],{"nctId":153,"briefTitle":154,"status":107,"phases":155,"primaryCompletion":156,"completion":157,"start":158,"enrollment":19,"conditions":159,"interventions":161},"NCT02167620","Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness",[90],"2018-02","2018-03","2014-06",[160,15],"Diabetes Mellitus, Type 2",[140],{"nctId":163,"briefTitle":164,"status":125,"phases":165,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":173},"NCT05744479","Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability",[90],"2027-03-01","2023-02-28",100,[170,171,172],"Intellectual Disability","Developmental Disability","Obesity",[140],{"trials":175,"activeCount":99},[],{"intervention":177,"totalTrials":136,"cells":178},"Varenicline 1mg BID",{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":185,"PHASE4":187,"NA":202},{"trials":180,"activeCount":99},[],{"trials":182,"activeCount":99},[],{"trials":184,"activeCount":99},[],{"trials":186,"activeCount":99},[],{"trials":188,"activeCount":136,"soonestReadout":193},[189],{"nctId":190,"briefTitle":191,"status":125,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":201},"NCT06798324","tDCS Plus Varenicline for Smoking Cessation",[90],"2028-01-20","2028-08-01","2025-03-10",160,[27,198,32,199,35,200],"Tobacco Smoking","Nicotine Use Disorder","Substance Use Disorders",[177],{"trials":203,"activeCount":99},[],{"intervention":42,"totalTrials":136,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":223},{"trials":207,"activeCount":99},[],{"trials":209,"activeCount":99},[],{"trials":211,"activeCount":99},[],{"trials":213,"activeCount":99},[],{"trials":215,"activeCount":136,"soonestReadout":41},[216],{"nctId":39,"briefTitle":40,"status":125,"phases":217,"primaryCompletion":41,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":222},[90],"2026-12-31","2022-11-30",1200,[27,198,32,199,200],[42],{"trials":224,"activeCount":99},[],{"intervention":135,"totalTrials":136,"cells":226},{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":233,"PHASE4":235,"NA":241},{"trials":228,"activeCount":99},[],{"trials":230,"activeCount":99},[],{"trials":232,"activeCount":99},[],{"trials":234,"activeCount":99},[],{"trials":236,"activeCount":136,"soonestReadout":127},[237],{"nctId":123,"briefTitle":124,"status":125,"phases":238,"primaryCompletion":127,"completion":128,"start":129,"enrollment":19,"conditions":239,"interventions":240},[90],[131,132,133],[94,135],{"trials":242,"activeCount":99},[],{"intervention":244,"totalTrials":136,"cells":245},"Olanzapine",{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":254,"NA":272},{"trials":247,"activeCount":99},[],{"trials":249,"activeCount":99},[],{"trials":251,"activeCount":99},[],{"trials":253,"activeCount":99},[],{"trials":255,"activeCount":136,"soonestReadout":260},[256],{"nctId":257,"briefTitle":258,"status":125,"phases":259,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":269},"NCT04478838","\"Extended\" (Alternate Day) Antipsychotic Dosing",[90],"2027-09-30","2028-09-30","2022-06-06",120,[265,266,267,268],"Schizophrenia and Related Disorders","Drug Administration Schedule","Drug Therapy","Antipsychotic Agents",[270,244,271],"Risperidone","paliperidone",{"trials":273,"activeCount":99},[],{"intervention":271,"totalTrials":136,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":290},{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":99},[],{"trials":283,"activeCount":99},[],{"trials":285,"activeCount":136,"soonestReadout":260},[286],{"nctId":257,"briefTitle":258,"status":125,"phases":287,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":288,"interventions":289},[90],[265,266,267,268],[270,244,271],{"trials":291,"activeCount":99},[],{"intervention":84,"totalTrials":136,"cells":293},{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":312},{"trials":295,"activeCount":99},[],{"trials":297,"activeCount":99},[],{"trials":299,"activeCount":99},[],{"trials":301,"activeCount":99},[],{"trials":303,"activeCount":136,"soonestReadout":83},[304],{"nctId":81,"briefTitle":82,"status":125,"phases":305,"primaryCompletion":83,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":311},[90],"2026-12-01","2024-09-01",40,[35,310,27],"Psychiatric Disorder",[84],{"trials":313,"activeCount":99},[],{"intervention":315,"totalTrials":9,"cells":316},"Clozapine",{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":325,"NA":345},{"trials":318,"activeCount":99},[],{"trials":320,"activeCount":99},[],{"trials":322,"activeCount":99},[],{"trials":324,"activeCount":99},[],{"trials":326,"activeCount":136,"soonestReadout":340},[327,336],{"nctId":328,"briefTitle":329,"status":107,"phases":330,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":335},"NCT02640300","Switching Antipsychotics: Abrupt Discontinuation Versus Overlap",[90],"2004-07","1999-05",33,[15,24],[315],{"nctId":337,"briefTitle":338,"status":125,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":344},"NCT02639702","Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia",[90],"2026-12","2016-08",30,[15,24],[315],{"trials":346,"activeCount":99},[347],{"nctId":348,"briefTitle":349,"status":350,"phases":351,"primaryCompletion":352,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":356},"NCT02714894","Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study","UNKNOWN",[],"2022-07-30","2016-04",108,[15],[315],{"intervention":270,"totalTrials":95,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":373},{"trials":360,"activeCount":99},[],{"trials":362,"activeCount":99},[],{"trials":364,"activeCount":99},[],{"trials":366,"activeCount":99},[],{"trials":368,"activeCount":136,"soonestReadout":260},[369],{"nctId":257,"briefTitle":258,"status":125,"phases":370,"primaryCompletion":260,"completion":261,"start":262,"enrollment":263,"conditions":371,"interventions":372},[90],[265,266,267,268],[270,244,271],{"trials":374,"activeCount":99},[375],{"nctId":376,"briefTitle":377,"status":350,"phases":378,"primaryCompletion":379,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":384},"NCT00825045","Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia",[91],"2020-12","2008-12",14,[15,24,383],"Schizophreniform Disorder",[385],"risperidone",{"intervention":47,"totalTrials":387,"cells":388},4,{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":411,"PHASE3":431,"PHASE4":433,"NA":435},{"trials":390,"activeCount":99},[],{"trials":392,"activeCount":95,"soonestReadout":46},[393,400],{"nctId":44,"briefTitle":45,"status":394,"phases":395,"primaryCompletion":46,"completion":65,"start":307,"enrollment":396,"conditions":397,"interventions":399},"ENROLLING_BY_INVITATION",[87],10,[398],"Obsessive-Compulsive Disorder",[47],{"nctId":401,"briefTitle":402,"status":125,"phases":403,"primaryCompletion":404,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":410},"NCT06731621","Psilocybin for Treatment-Resistant Depression in Autism",[87],"2027-08","2024-11-01",20,[408,409],"Treatment Resistant Depression","Autism Spectrum Disorder",[47],{"trials":412,"activeCount":95,"soonestReadout":56},[413,424],{"nctId":414,"briefTitle":415,"status":416,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":308,"conditions":421,"interventions":423},"NCT07211438","Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression","NOT_YET_RECRUITING",[88],"2028-04-01","2028-12-01","2026-04-01",[422],"Treatment-Resistant Depression",[47],{"nctId":54,"briefTitle":55,"status":425,"phases":426,"primaryCompletion":56,"completion":56,"start":427,"enrollment":396,"conditions":428,"interventions":430},"ACTIVE_NOT_RECRUITING",[88],"2023-11-27",[429],"Amnestic Mild Cognitive Impairment",[47],{"trials":432,"activeCount":99},[],{"trials":434,"activeCount":99},[],{"trials":436,"activeCount":99},[],{"intervention":438,"totalTrials":387,"cells":439},"Psilocybin 25 mg",{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":441,"activeCount":99},[],{"trials":443,"activeCount":99},[],{"trials":445,"activeCount":9,"soonestReadout":461},[446,457,468,477],{"nctId":447,"briefTitle":448,"status":107,"phases":449,"primaryCompletion":450,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":455},"NCT05710237","Does Psilocybin Require Psychedelic Effects to Treat Depression?",[88],"2026-04-14","2023-07-01",41,[454],"Treatment-resistant Depression",[438,456],"Risperidone 1 MG",{"nctId":458,"briefTitle":459,"status":125,"phases":460,"primaryCompletion":461,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":467},"NCT06518720","Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)",[88],"2027-03","2027-12","2025-04-01",16,[408,466],"Chronic Pain",[438],{"nctId":469,"briefTitle":470,"status":125,"phases":471,"primaryCompletion":472,"completion":473,"start":474,"enrollment":33,"conditions":475,"interventions":476},"NCT06512220","Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)",[88],"2027-04","2027-09","2025-04-21",[408],[438,456],{"nctId":478,"briefTitle":479,"status":416,"phases":480,"primaryCompletion":481,"completion":482,"start":483,"enrollment":342,"conditions":484,"interventions":487},"NCT07405606","Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder",[88],"2028-03","2028-06","2026-03",[485,486],"Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)",[438],{"trials":489,"activeCount":99},[],{"trials":491,"activeCount":99},[],{"trials":493,"activeCount":99},[],{"intervention":456,"totalTrials":95,"cells":495},{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":510,"PHASE4":512,"NA":514},{"trials":497,"activeCount":99},[],{"trials":499,"activeCount":99},[],{"trials":501,"activeCount":136,"soonestReadout":472},[502,506],{"nctId":447,"briefTitle":448,"status":107,"phases":503,"primaryCompletion":450,"completion":450,"start":451,"enrollment":452,"conditions":504,"interventions":505},[88],[454],[438,456],{"nctId":469,"briefTitle":470,"status":125,"phases":507,"primaryCompletion":472,"completion":473,"start":474,"enrollment":33,"conditions":508,"interventions":509},[88],[408],[438,456],{"trials":511,"activeCount":99},[],{"trials":513,"activeCount":99},[],{"trials":515,"activeCount":99},[],{"intervention":52,"totalTrials":136,"cells":517},{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":531,"PHASE4":533,"NA":535},{"trials":519,"activeCount":99},[],{"trials":521,"activeCount":99},[],{"trials":523,"activeCount":136,"soonestReadout":51},[524],{"nctId":49,"briefTitle":50,"status":125,"phases":525,"primaryCompletion":51,"completion":51,"start":526,"enrollment":527,"conditions":528,"interventions":530},[88],"2024-08-16",36,[529],"Alcohol Use Disorder",[52],{"trials":532,"activeCount":99},[],{"trials":534,"activeCount":99},[],{"trials":536,"activeCount":99},[],{"intervention":538,"totalTrials":95,"cells":539},"Insulin Lispro 100 UNT\u002FML",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":550,"PHASE3":552,"PHASE4":554,"NA":556},{"trials":541,"activeCount":99},[],{"trials":543,"activeCount":136,"soonestReadout":60},[544],{"nctId":58,"briefTitle":59,"status":425,"phases":545,"primaryCompletion":60,"completion":60,"start":546,"enrollment":547,"conditions":548,"interventions":549},[87],"2019-10-22",64,[132],[61,538],{"trials":551,"activeCount":99},[],{"trials":553,"activeCount":99},[],{"trials":555,"activeCount":99},[],{"trials":557,"activeCount":136,"soonestReadout":74},[558],{"nctId":72,"briefTitle":73,"status":125,"phases":559,"primaryCompletion":74,"completion":74,"start":560,"enrollment":561,"conditions":562,"interventions":567},[91],"2024-06-03",15,[563,564,565,566],"Insulin Resistance","Menstrual Cycle","Type 2 Diabetes","Antipsychotics",[75,538,568],"Saline",{"intervention":61,"totalTrials":136,"cells":570},{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":579,"PHASE3":581,"PHASE4":583,"NA":585},{"trials":572,"activeCount":99},[],{"trials":574,"activeCount":136,"soonestReadout":60},[575],{"nctId":58,"briefTitle":59,"status":425,"phases":576,"primaryCompletion":60,"completion":60,"start":546,"enrollment":547,"conditions":577,"interventions":578},[87],[132],[61,538],{"trials":580,"activeCount":99},[],{"trials":582,"activeCount":99},[],{"trials":584,"activeCount":99},[],{"trials":586,"activeCount":99},[],{"intervention":588,"totalTrials":387,"cells":589},"Cannabis",{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":607,"PHASE4":609,"NA":611},{"trials":591,"activeCount":99},[],{"trials":593,"activeCount":99},[],{"trials":595,"activeCount":99},[596],{"nctId":597,"briefTitle":598,"status":107,"phases":599,"primaryCompletion":600,"completion":600,"start":601,"enrollment":527,"conditions":602,"interventions":606},"NCT03656029","Dose-response of Cannabis and Driving",[88],"2022-06-14","2021-06-04",[603,604,605],"Driving Impaired","Cognitive Impairment","Abuse Cannabis",[588],{"trials":608,"activeCount":99},[],{"trials":610,"activeCount":99},[],{"trials":612,"activeCount":9,"soonestReadout":636},[613,622,632],{"nctId":614,"briefTitle":615,"status":125,"phases":616,"primaryCompletion":461,"completion":461,"start":617,"enrollment":618,"conditions":619,"interventions":620},"NCT04325958","Age Differences in the Effects of Cannabis on Simulated Driving",[91],"2024-03-27",128,[588],[588,621],"Placebos",{"nctId":623,"briefTitle":624,"status":416,"phases":625,"primaryCompletion":626,"completion":261,"start":627,"enrollment":628,"conditions":629,"interventions":631},"NCT07105449","THC Titration of High-Potency Cannabis Concentrates",[91],"2028-03-31","2025-10-01",48,[630],"THC",[588,588,588],{"nctId":633,"briefTitle":634,"status":125,"phases":635,"primaryCompletion":636,"completion":166,"start":637,"enrollment":112,"conditions":638,"interventions":640},"NCT05526196","Combined and Separate Effects of Cannabis and Tobacco: Psychomotor, Subjective and Physiological Outcomes",[91],"2027-02-01","2024-10-07",[639],"Driving Under the Influence",[588,641,642],"Tobacco","Cannabis tobacco",{"intervention":621,"totalTrials":95,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":666},{"trials":646,"activeCount":99},[],{"trials":648,"activeCount":99},[],{"trials":650,"activeCount":99},[],{"trials":652,"activeCount":99},[],{"trials":654,"activeCount":99},[655],{"nctId":656,"briefTitle":657,"status":107,"phases":658,"primaryCompletion":659,"completion":660,"start":661,"enrollment":662,"conditions":663,"interventions":664},"NCT03000387","Personalized Dosing of Nicotine Replacement (NRT to Effect)",[90],"2023-02-27","2023-12-11","2018-01-23",211,[35,27],[665,621],"Nicotine Patch",{"trials":667,"activeCount":136,"soonestReadout":461},[668],{"nctId":614,"briefTitle":615,"status":125,"phases":669,"primaryCompletion":461,"completion":461,"start":617,"enrollment":618,"conditions":670,"interventions":671},[91],[588],[588,621],{"intervention":70,"totalTrials":95,"cells":673},{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":689,"PHASE4":691,"NA":693},{"trials":675,"activeCount":99},[],{"trials":677,"activeCount":99},[],{"trials":679,"activeCount":99},[680],{"nctId":681,"briefTitle":682,"status":683,"phases":684,"start":685,"enrollment":99,"conditions":686,"interventions":688},"NCT00370188","Topiramate on Gambling-Related Behaviours","WITHDRAWN",[88],"2006-09",[687],"Gambling",[70],{"trials":690,"activeCount":99},[],{"trials":692,"activeCount":99},[],{"trials":694,"activeCount":136,"soonestReadout":65},[695],{"nctId":68,"briefTitle":69,"status":425,"phases":696,"primaryCompletion":65,"completion":65,"start":697,"enrollment":698,"conditions":699,"interventions":701},[91],"2016-05",50,[700],"Schizophrenia, Schizoaffective Disorder",[70],{"intervention":641,"totalTrials":136,"cells":703},{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":714},{"trials":705,"activeCount":99},[],{"trials":707,"activeCount":99},[],{"trials":709,"activeCount":99},[],{"trials":711,"activeCount":99},[],{"trials":713,"activeCount":99},[],{"trials":715,"activeCount":136,"soonestReadout":636},[716],{"nctId":633,"briefTitle":634,"status":125,"phases":717,"primaryCompletion":636,"completion":166,"start":637,"enrollment":112,"conditions":718,"interventions":719},[91],[639],[588,641,642],{"intervention":642,"totalTrials":136,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":730,"NA":732},{"trials":723,"activeCount":99},[],{"trials":725,"activeCount":99},[],{"trials":727,"activeCount":99},[],{"trials":729,"activeCount":99},[],{"trials":731,"activeCount":99},[],{"trials":733,"activeCount":136,"soonestReadout":636},[734],{"nctId":633,"briefTitle":634,"status":125,"phases":735,"primaryCompletion":636,"completion":166,"start":637,"enrollment":112,"conditions":736,"interventions":737},[91],[639],[588,641,642],{"intervention":66,"totalTrials":136,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":741,"activeCount":99},[],{"trials":743,"activeCount":99},[],{"trials":745,"activeCount":99},[],{"trials":747,"activeCount":99},[],{"trials":749,"activeCount":99},[],{"trials":751,"activeCount":136,"soonestReadout":65},[752],{"nctId":63,"briefTitle":64,"status":425,"phases":753,"primaryCompletion":65,"completion":65,"start":754,"enrollment":755,"conditions":756,"interventions":758},[91],"2022-05-25",92,[757],"Schizophrenia Spectrum Disorders",[66],{"intervention":75,"totalTrials":136,"cells":760},{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":769,"NA":771},{"trials":762,"activeCount":99},[],{"trials":764,"activeCount":99},[],{"trials":766,"activeCount":99},[],{"trials":768,"activeCount":99},[],{"trials":770,"activeCount":99},[],{"trials":772,"activeCount":136,"soonestReadout":74},[773],{"nctId":72,"briefTitle":73,"status":125,"phases":774,"primaryCompletion":74,"completion":74,"start":560,"enrollment":561,"conditions":775,"interventions":776},[91],[563,564,565,566],[75,538,568],{"intervention":568,"totalTrials":136,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":785,"PHASE4":787,"NA":789},{"trials":780,"activeCount":99},[],{"trials":782,"activeCount":99},[],{"trials":784,"activeCount":99},[],{"trials":786,"activeCount":99},[],{"trials":788,"activeCount":99},[],{"trials":790,"activeCount":136,"soonestReadout":74},[791],{"nctId":72,"briefTitle":73,"status":125,"phases":792,"primaryCompletion":74,"completion":74,"start":560,"enrollment":561,"conditions":793,"interventions":794},[91],[563,564,565,566],[75,538,568],{"intervention":79,"totalTrials":136,"cells":796},{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":798,"activeCount":99},[],{"trials":800,"activeCount":99},[],{"trials":802,"activeCount":99},[],{"trials":804,"activeCount":99},[],{"trials":806,"activeCount":99},[],{"trials":808,"activeCount":136,"soonestReadout":74},[809],{"nctId":77,"briefTitle":78,"status":125,"phases":810,"primaryCompletion":74,"completion":74,"start":811,"enrollment":406,"conditions":812,"interventions":814},[91],"2023-04-01",[15,813],"Healthy",[79],{"intervention":816,"totalTrials":95,"cells":817},"Nabilone Oral",{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":834,"PHASE4":836,"NA":846},{"trials":819,"activeCount":99},[],{"trials":821,"activeCount":99},[],{"trials":823,"activeCount":99},[824],{"nctId":825,"briefTitle":826,"status":827,"phases":828,"primaryCompletion":829,"completion":829,"start":830,"enrollment":25,"conditions":831,"interventions":832},"NCT04801641","A Pilot Trial of Nabilone for the Treatment of Obesity","TERMINATED",[88],"2023-08-14","2021-09-17",[172],[833],"Nabilone",{"trials":835,"activeCount":99},[],{"trials":837,"activeCount":99},[838],{"nctId":839,"briefTitle":840,"status":107,"phases":841,"primaryCompletion":842,"completion":842,"start":843,"enrollment":396,"conditions":844,"interventions":845},"NCT05885685","Investigating the Effects of Nabilone on Endocannabinoid Metabolism",[90],"2025-12-05","2023-10-31",[813],[816],{"trials":847,"activeCount":99},[],{"intervention":849,"totalTrials":136,"cells":850},"Aripiprazole Augmentation",{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":859,"NA":879},{"trials":852,"activeCount":99},[],{"trials":854,"activeCount":99},[],{"trials":856,"activeCount":99},[],{"trials":858,"activeCount":99},[],{"trials":860,"activeCount":99},[861],{"nctId":862,"briefTitle":863,"status":107,"phases":864,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":868,"interventions":874},"NCT05531591","RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)",[90],"2024-07-31","2019-08-01",87,[21,869,870,408,18,871,872,873],"Dementia","Mild Cognitive Impairment","Treatment-Refractory Depression","Late Life Depression","Geriatric Depression",[849,875,876,877,878],"Bupropion Augmentation","Switch to bupropion","Lithium Augmentation","Switch to nortriptyline",{"trials":880,"activeCount":99},[],{"intervention":875,"totalTrials":136,"cells":882},{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":891,"NA":897},{"trials":884,"activeCount":99},[],{"trials":886,"activeCount":99},[],{"trials":888,"activeCount":99},[],{"trials":890,"activeCount":99},[],{"trials":892,"activeCount":99},[893],{"nctId":862,"briefTitle":863,"status":107,"phases":894,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":895,"interventions":896},[90],[21,869,870,408,18,871,872,873],[849,875,876,877,878],{"trials":898,"activeCount":99},[],{"intervention":876,"totalTrials":136,"cells":900},{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":909,"NA":915},{"trials":902,"activeCount":99},[],{"trials":904,"activeCount":99},[],{"trials":906,"activeCount":99},[],{"trials":908,"activeCount":99},[],{"trials":910,"activeCount":99},[911],{"nctId":862,"briefTitle":863,"status":107,"phases":912,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":913,"interventions":914},[90],[21,869,870,408,18,871,872,873],[849,875,876,877,878],{"trials":916,"activeCount":99},[],{"intervention":877,"totalTrials":136,"cells":918},{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":925,"PHASE4":927,"NA":933},{"trials":920,"activeCount":99},[],{"trials":922,"activeCount":99},[],{"trials":924,"activeCount":99},[],{"trials":926,"activeCount":99},[],{"trials":928,"activeCount":99},[929],{"nctId":862,"briefTitle":863,"status":107,"phases":930,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":931,"interventions":932},[90],[21,869,870,408,18,871,872,873],[849,875,876,877,878],{"trials":934,"activeCount":99},[],{"intervention":878,"totalTrials":136,"cells":936},{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":943,"PHASE4":945,"NA":951},{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":99},[],{"trials":942,"activeCount":99},[],{"trials":944,"activeCount":99},[],{"trials":946,"activeCount":99},[947],{"nctId":862,"briefTitle":863,"status":107,"phases":948,"primaryCompletion":865,"completion":865,"start":866,"enrollment":867,"conditions":949,"interventions":950},[90],[21,869,870,408,18,871,872,873],[849,875,876,877,878],{"trials":952,"activeCount":99},[],{"intervention":954,"totalTrials":136,"cells":955},"bupropion HCl",{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":962,"PHASE4":964,"NA":977},{"trials":957,"activeCount":99},[],{"trials":959,"activeCount":99},[],{"trials":961,"activeCount":99},[],{"trials":963,"activeCount":99},[],{"trials":965,"activeCount":99},[966],{"nctId":967,"briefTitle":968,"status":107,"phases":969,"primaryCompletion":970,"completion":970,"start":971,"enrollment":972,"conditions":973,"interventions":976},"NCT01015170","STOP Study: Effectiveness of Zyban in a Clinical Population",[90],"2015-10","2009-10",454,[974,975,32],"Cigarette Smoking","Nicotine Addiction",[954],{"trials":978,"activeCount":99},[],{"intervention":980,"totalTrials":136,"cells":981},"Nicotine",{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":988,"PHASE4":990,"NA":1002},{"trials":983,"activeCount":99},[],{"trials":985,"activeCount":99},[],{"trials":987,"activeCount":99},[],{"trials":989,"activeCount":99},[],{"trials":991,"activeCount":99},[992],{"nctId":993,"briefTitle":994,"status":107,"phases":995,"primaryCompletion":996,"completion":996,"start":997,"enrollment":998,"conditions":999,"interventions":1001},"NCT02108626","Electronic Cigarettes in Daily Dependent Smokers",[90],"2015-04","2014-03",43,[1000,27],"Substance Withdrawal Syndrome",[980],{"trials":1003,"activeCount":99},[],{"intervention":1005,"totalTrials":136,"cells":1006},"Cytisine",{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1015,"NA":1025},{"trials":1008,"activeCount":99},[],{"trials":1010,"activeCount":99},[],{"trials":1012,"activeCount":99},[],{"trials":1014,"activeCount":99},[],{"trials":1016,"activeCount":99},[1017],{"nctId":1018,"briefTitle":1019,"status":107,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":1022,"enrollment":406,"conditions":1023,"interventions":1024},"NCT05729243","Cytisine for Smoking Cessation",[90],"2025-12-12","2023-02-08",[35,529,32],[1005],{"trials":1026,"activeCount":99},[],{"intervention":1028,"totalTrials":136,"cells":1029},"Xyrem",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1038,"NA":1050},{"trials":1031,"activeCount":99},[],{"trials":1033,"activeCount":99},[],{"trials":1035,"activeCount":99},[],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[1040],{"nctId":1041,"briefTitle":1042,"status":107,"phases":1043,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":1046,"conditions":1047,"interventions":1049},"NCT02637076","Xyrem and Brain Dopamine in Narcolepsy",[90],"2020-01-23","2016-01",17,[1048,132],"Narcolepsy With Cataplexy",[1028],{"trials":1051,"activeCount":99},[],{"intervention":1053,"totalTrials":136,"cells":1054},"Apo-Oxycodone CR®",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1061,"PHASE4":1063,"NA":1075},{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"trials":1060,"activeCount":99},[],{"trials":1062,"activeCount":99},[],{"trials":1064,"activeCount":99},[1065],{"nctId":1066,"briefTitle":1067,"status":107,"phases":1068,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":36,"conditions":1071,"interventions":1073},"NCT02101840","Abuse Liability of Controlled-Release Oxycodone Formulations",[90],"2014-12","2014-02",[1072],"Substance-Related Disorders",[1053,1074],"OxyNEO®",{"trials":1076,"activeCount":99},[],{"intervention":1074,"totalTrials":136,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1087,"NA":1093},{"trials":1080,"activeCount":99},[],{"trials":1082,"activeCount":99},[],{"trials":1084,"activeCount":99},[],{"trials":1086,"activeCount":99},[],{"trials":1088,"activeCount":99},[1089],{"nctId":1066,"briefTitle":1067,"status":107,"phases":1090,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":36,"conditions":1091,"interventions":1092},[90],[1072],[1053,1074],{"trials":1094,"activeCount":99},[],{"intervention":1096,"totalTrials":136,"cells":1097},"Pregabalin",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1115},{"trials":1099,"activeCount":99},[],{"trials":1101,"activeCount":99},[],{"trials":1103,"activeCount":99},[],{"trials":1105,"activeCount":99},[],{"trials":1107,"activeCount":99},[1108],{"nctId":1109,"briefTitle":1110,"status":827,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":996,"enrollment":136,"conditions":1113,"interventions":1114},"NCT02423018","Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms",[90],"2016-03",[1072],[1096],{"trials":1116,"activeCount":99},[],{"intervention":1118,"totalTrials":136,"cells":1119},"Antidepressants",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1138},{"trials":1121,"activeCount":99},[],{"trials":1123,"activeCount":99},[],{"trials":1125,"activeCount":99},[],{"trials":1127,"activeCount":99},[],{"trials":1129,"activeCount":99},[1130],{"nctId":1131,"briefTitle":1132,"status":107,"phases":1133,"primaryCompletion":1134,"completion":1134,"start":331,"enrollment":1135,"conditions":1136,"interventions":1137},"NCT00183560","Preventing Depression Relapse With Mindfulness-Based Cognitive Therapy",[90],"2010-10",184,[21],[1118],{"trials":1139,"activeCount":99},[],{"intervention":1141,"totalTrials":136,"cells":1142},"Control",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1149,"PHASE4":1151,"NA":1162},{"trials":1144,"activeCount":99},[],{"trials":1146,"activeCount":99},[],{"trials":1148,"activeCount":99},[],{"trials":1150,"activeCount":99},[],{"trials":1152,"activeCount":99},[1153],{"nctId":1154,"briefTitle":1155,"status":827,"phases":1156,"primaryCompletion":997,"completion":997,"start":1157,"enrollment":95,"conditions":1158,"interventions":1160},"NCT01638377","Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers",[90],"2012-08",[1159],"Alcohol Dependence",[1161,1141],"Naltrexone",{"trials":1163,"activeCount":99},[],{"intervention":1165,"totalTrials":136,"cells":1166},"Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain",{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1173,"PHASE4":1175,"NA":1189},{"trials":1168,"activeCount":99},[],{"trials":1170,"activeCount":99},[],{"trials":1172,"activeCount":99},[],{"trials":1174,"activeCount":99},[],{"trials":1176,"activeCount":99},[1177],{"nctId":1178,"briefTitle":1179,"status":107,"phases":1180,"primaryCompletion":1181,"completion":1182,"start":1183,"enrollment":1184,"conditions":1185,"interventions":1188},"NCT04484610","Appropriate Opioid Quantities for Acute Pain - Pharmacist Study",[90],"2022-02-21","2022-03-31","2020-09-08",205,[1186,1187],"Opioid Use","Acute Pain",[1165],{"trials":1190,"activeCount":99},[],{"intervention":1192,"totalTrials":95,"cells":1193},"Minocycline",{"EARLY_PHASE1":1194,"PHASE1":1206,"PHASE2":1208,"PHASE3":1210,"PHASE4":1221,"NA":1223},{"trials":1195,"activeCount":99},[1196],{"nctId":1197,"briefTitle":1198,"status":107,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1204},"NCT02362529","Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder",[86],"2019-04","2015-02",115,[18],[1192,1205],"Celecoxib",{"trials":1207,"activeCount":99},[],{"trials":1209,"activeCount":99},[],{"trials":1211,"activeCount":99},[1212],{"nctId":1213,"briefTitle":1214,"status":107,"phases":1215,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1220},"NCT03947827","Minocycline as Adjunctive Treatment for Treatment Resistant Depression",[89],"2025-01-07","2020-02-01",76,[408],[1192],{"trials":1222,"activeCount":99},[],{"trials":1224,"activeCount":99},[],{"intervention":1226,"totalTrials":136,"cells":1227},"Nicotine mouthspray",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1245,"NA":1247},{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":99},[],{"trials":1235,"activeCount":99},[1236],{"nctId":1237,"briefTitle":1238,"status":827,"phases":1239,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":25,"conditions":1242,"interventions":1243},"NCT02439944","Efficacy and Neural Correlates of Personalized Treatment With Transdermal Nicotine Replacement",[88,89],"2017-12","2015-07",[35,27],[1244,1226],"Nicotine patch",{"trials":1246,"activeCount":99},[],{"trials":1248,"activeCount":99},[],{"intervention":1250,"totalTrials":95,"cells":1251},"Antidepressant medication",{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1264,"PHASE3":1273,"PHASE4":1275,"NA":1277},{"trials":1253,"activeCount":99},[],{"trials":1255,"activeCount":99},[1256],{"nctId":1257,"briefTitle":1258,"status":107,"phases":1259,"primaryCompletion":1260,"start":1261,"enrollment":8,"conditions":1262,"interventions":1263},"NCT00745017","Stress Generation and Recurrent Depression: The Role of Differential Treatment Response",[87],"2006-07","2001-07",[21,18],[1250],{"trials":1265,"activeCount":99},[1266],{"nctId":1267,"briefTitle":1268,"status":107,"phases":1269,"primaryCompletion":685,"start":1270,"enrollment":8,"conditions":1271,"interventions":1272},"NCT00744406","Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression",[88],"2003-07",[21,18],[1250],{"trials":1274,"activeCount":99},[],{"trials":1276,"activeCount":99},[],{"trials":1278,"activeCount":99},[],{"intervention":1280,"totalTrials":136,"cells":1281},"Melatonin",{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1297,"PHASE4":1299,"NA":1301},{"trials":1283,"activeCount":99},[],{"trials":1285,"activeCount":99},[],{"trials":1287,"activeCount":99},[1288],{"nctId":1289,"briefTitle":1290,"status":107,"phases":1291,"primaryCompletion":1292,"completion":1292,"start":1293,"enrollment":112,"conditions":1294,"interventions":1296},"NCT03043443","Melatonin Use for Sleep Problems in Alcohol Dependent Patients",[88],"2019-01-10","2017-01-25",[1295],"Alcohol-Related Disorders",[1280],{"trials":1298,"activeCount":99},[],{"trials":1300,"activeCount":99},[],{"trials":1302,"activeCount":99},[],{"intervention":1304,"totalTrials":136,"cells":1305},"Methylphenidate",{"EARLY_PHASE1":1306,"PHASE1":1308,"PHASE2":1310,"PHASE3":1321,"PHASE4":1323,"NA":1325},{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":99},[1312],{"nctId":1313,"briefTitle":1314,"status":107,"phases":1315,"primaryCompletion":110,"completion":110,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1320},"NCT01921582","A Comparison of Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Binge Eating Disorder",[88],"2013-08",51,[1319],"Binge-Eating Disorder",[1304],{"trials":1322,"activeCount":99},[],{"trials":1324,"activeCount":99},[],{"trials":1326,"activeCount":99},[],{"intervention":1328,"totalTrials":136,"cells":1329},"Prazosin",{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1331,"activeCount":99},[],{"trials":1333,"activeCount":99},[],{"trials":1335,"activeCount":99},[1336],{"nctId":1337,"briefTitle":1338,"status":827,"phases":1339,"primaryCompletion":1340,"completion":1340,"start":1341,"enrollment":136,"conditions":1342,"interventions":1343},"NCT01642433","Prazosin for Smoking Cessation",[88],"2013-09","2012-07",[27],[1328],{"trials":1345,"activeCount":99},[],{"trials":1347,"activeCount":99},[],{"trials":1349,"activeCount":99},[],{"intervention":1351,"totalTrials":136,"cells":1352},"buprenorphine",{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1357,"PHASE3":1369,"PHASE4":1371,"NA":1373},{"trials":1354,"activeCount":99},[],{"trials":1356,"activeCount":99},[],{"trials":1358,"activeCount":99},[1359],{"nctId":1360,"briefTitle":1361,"status":107,"phases":1362,"primaryCompletion":1363,"completion":1364,"start":1069,"enrollment":1365,"conditions":1366,"interventions":1367},"NCT02263248","Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine",[87,88],"2017-01-19","2018-05-01",56,[18,21],[1368,1351],"venlafaxine",{"trials":1370,"activeCount":99},[],{"trials":1372,"activeCount":99},[],{"trials":1374,"activeCount":99},[],{"intervention":1376,"totalTrials":136,"cells":1377},"Motherwell",{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1379,"activeCount":99},[],{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[1384],{"nctId":1385,"briefTitle":1386,"status":107,"phases":1387,"primaryCompletion":353,"completion":353,"start":1070,"enrollment":22,"conditions":1388,"interventions":1390},"NCT02073175","Development of Dietary Supplements for Mood Symptoms in Postpartum",[88],[1389,813],"Postpartum Blues",[1376],{"trials":1392,"activeCount":99},[],{"trials":1394,"activeCount":99},[],{"trials":1396,"activeCount":99},[],{"intervention":1398,"totalTrials":136,"cells":1399},"Baclofen 30 mg\u002Fday",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1414,"PHASE4":1416,"NA":1418},{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":99},[],{"trials":1405,"activeCount":99},[1406],{"nctId":1407,"briefTitle":1408,"status":827,"phases":1409,"primaryCompletion":1157,"completion":1157,"start":1134,"enrollment":1410,"conditions":1411,"interventions":1412},"NCT01228994","Baclofen for Smoking Cessation in a Non-Psychiatric Population",[88],6,[27],[1398,1413],"Baclofen 60 mg\u002Fday",{"trials":1415,"activeCount":99},[],{"trials":1417,"activeCount":99},[],{"trials":1419,"activeCount":99},[],{"intervention":1413,"totalTrials":136,"cells":1421},{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1423,"activeCount":99},[],{"trials":1425,"activeCount":99},[],{"trials":1427,"activeCount":99},[1428],{"nctId":1407,"briefTitle":1408,"status":827,"phases":1429,"primaryCompletion":1157,"completion":1157,"start":1134,"enrollment":1410,"conditions":1430,"interventions":1431},[88],[27],[1398,1413],{"trials":1433,"activeCount":99},[],{"trials":1435,"activeCount":99},[],{"trials":1437,"activeCount":99},[],{"intervention":1439,"totalTrials":136,"cells":1440},"Cannabis Sativa",{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1456,"PHASE4":1458,"NA":1460},{"trials":1442,"activeCount":99},[],{"trials":1444,"activeCount":99},[],{"trials":1446,"activeCount":99},[1447],{"nctId":1448,"briefTitle":1449,"status":107,"phases":1450,"primaryCompletion":1451,"completion":1451,"start":1452,"enrollment":396,"conditions":1453,"interventions":1455},"NCT03813602","Detection of Cannabis Impairment With an Eye Tracker",[87,88],"2019-11-15","2019-08-15",[1454],"Cannabis Intoxication",[1439],{"trials":1457,"activeCount":99},[],{"trials":1459,"activeCount":99},[],{"trials":1461,"activeCount":99},[],{"intervention":1463,"totalTrials":136,"cells":1464},"levodopa\u002Fcarbidopa",{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1466,"activeCount":99},[],{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":99},[1471],{"nctId":1472,"briefTitle":1473,"status":107,"phases":1474,"primaryCompletion":1475,"completion":1045,"start":1476,"enrollment":30,"conditions":1477,"interventions":1478},"NCT01636037","Antipsychotic Augmentation With L-Dopa",[88],"2015-12","2012-09",[15],[1463],{"trials":1480,"activeCount":99},[],{"trials":1482,"activeCount":99},[],{"trials":1484,"activeCount":99},[],{"intervention":1486,"totalTrials":136,"cells":1487},"Gemfibrozil",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[1494],{"nctId":1495,"briefTitle":1496,"status":107,"phases":1497,"primaryCompletion":1498,"completion":1498,"start":1070,"enrollment":22,"conditions":1499,"interventions":1500},"NCT01876810","Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction",[88],"2016-02",[27],[1486],{"trials":1502,"activeCount":99},[],{"trials":1504,"activeCount":99},[],{"trials":1506,"activeCount":99},[],{"intervention":1508,"totalTrials":136,"cells":1509},"Naltrexone 380 MG [Vivitrol]",{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1511,"activeCount":99},[],{"trials":1513,"activeCount":99},[],{"trials":1515,"activeCount":99},[1516],{"nctId":1517,"briefTitle":1518,"status":827,"phases":1519,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":136,"conditions":1523,"interventions":1525},"NCT04139668","Vivitrol Treatment for Cannabis Use Disorder",[88],"2021-10-28","2022-06-13","2021-06-09",[1524],"Cannabis Use Disorder",[1508],{"trials":1527,"activeCount":99},[],{"trials":1529,"activeCount":99},[],{"trials":1531,"activeCount":99},[],{"intervention":1533,"totalTrials":136,"cells":1534},"BP1.3656",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1550,"PHASE4":1552,"NA":1554},{"trials":1536,"activeCount":99},[],{"trials":1538,"activeCount":99},[],{"trials":1540,"activeCount":99},[1541],{"nctId":1542,"briefTitle":1543,"status":107,"phases":1544,"primaryCompletion":1545,"completion":1545,"start":1546,"enrollment":1547,"conditions":1548,"interventions":1549},"NCT04727086","Role of BP1.3656 on Alcohol Responses",[88],"2022-08-31","2021-02-01",37,[529],[1533],{"trials":1551,"activeCount":99},[],{"trials":1553,"activeCount":99},[],{"trials":1555,"activeCount":99},[],{"intervention":1557,"totalTrials":136,"cells":1558},"Propranolol",{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1563,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1560,"activeCount":99},[],{"trials":1562,"activeCount":99},[],{"trials":1564,"activeCount":99},[1565],{"nctId":1566,"briefTitle":1567,"status":350,"phases":1568,"primaryCompletion":1569,"completion":1569,"start":1570,"enrollment":628,"conditions":1571,"interventions":1573},"NCT05692271","Testing a Novel Therapeutic Strategy for Comorbid Post-Traumatic Stress Disorder and Alcohol Use Disorder",[88],"2025-02","2023-07-15",[1572,529],"Stress Disorders, Post-Traumatic",[1557],{"trials":1575,"activeCount":99},[],{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"intervention":1581,"totalTrials":136,"cells":1582},"Buspirone",{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1587,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1584,"activeCount":99},[],{"trials":1586,"activeCount":99},[],{"trials":1588,"activeCount":99},[1589],{"nctId":1590,"briefTitle":1591,"status":107,"phases":1592,"primaryCompletion":158,"completion":158,"start":1593,"enrollment":1410,"conditions":1594,"interventions":1596},"NCT01699828","Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET",[87,88],"2012-10",[32,1595],"Tobacco Use Cessation",[1581],{"trials":1598,"activeCount":99},[],{"trials":1600,"activeCount":99},[],{"trials":1602,"activeCount":99},[],{"intervention":1604,"totalTrials":136,"cells":1605},"Naloxone",{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1610,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1607,"activeCount":99},[],{"trials":1609,"activeCount":99},[],{"trials":1611,"activeCount":99},[1612],{"nctId":1613,"briefTitle":1614,"status":107,"phases":1615,"primaryCompletion":1616,"completion":1616,"start":1617,"enrollment":406,"conditions":1618,"interventions":1620},"NCT02137213","Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation",[88],"2015-03","2014-08",[1619],"Constipation",[1604],{"trials":1622,"activeCount":99},[],{"trials":1624,"activeCount":99},[],{"trials":1626,"activeCount":99},[],{"intervention":1628,"totalTrials":136,"cells":1629},"Dietary Supplement",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1646,"PHASE4":1648,"NA":1650},{"trials":1631,"activeCount":99},[],{"trials":1633,"activeCount":99},[],{"trials":1635,"activeCount":99},[1636],{"nctId":1637,"briefTitle":1638,"status":107,"phases":1639,"primaryCompletion":1112,"completion":1112,"start":1640,"enrollment":1641,"conditions":1642,"interventions":1644},"NCT02042521","A Dietary Supplement for Early Cigarette Withdrawal",[88],"2014-01",21,[1643],"Nicotine Dependence, Cigarettes, With Withdrawal",[1628,1645],"Lactose Placebo",{"trials":1647,"activeCount":99},[],{"trials":1649,"activeCount":99},[],{"trials":1651,"activeCount":99},[],{"intervention":1645,"totalTrials":136,"cells":1653},{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1658,"PHASE3":1664,"PHASE4":1666,"NA":1668},{"trials":1655,"activeCount":99},[],{"trials":1657,"activeCount":99},[],{"trials":1659,"activeCount":99},[1660],{"nctId":1637,"briefTitle":1638,"status":107,"phases":1661,"primaryCompletion":1112,"completion":1112,"start":1640,"enrollment":1641,"conditions":1662,"interventions":1663},[88],[1643],[1628,1645],{"trials":1665,"activeCount":99},[],{"trials":1667,"activeCount":99},[],{"trials":1669,"activeCount":99},[],{"intervention":116,"totalTrials":136,"cells":1671},{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1682,"PHASE4":1684,"NA":1686},{"trials":1673,"activeCount":99},[],{"trials":1675,"activeCount":99},[],{"trials":1677,"activeCount":99},[1678],{"nctId":105,"briefTitle":106,"status":107,"phases":1679,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":1680,"interventions":1681},[88],[114],[94,116,117],{"trials":1683,"activeCount":99},[],{"trials":1685,"activeCount":99},[],{"trials":1687,"activeCount":99},[],{"intervention":117,"totalTrials":136,"cells":1689},{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1700,"PHASE4":1702,"NA":1704},{"trials":1691,"activeCount":99},[],{"trials":1693,"activeCount":99},[],{"trials":1695,"activeCount":99},[1696],{"nctId":105,"briefTitle":106,"status":107,"phases":1697,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":1698,"interventions":1699},[88],[114],[94,116,117],{"trials":1701,"activeCount":99},[],{"trials":1703,"activeCount":99},[],{"trials":1705,"activeCount":99},[],{"intervention":1707,"totalTrials":136,"cells":1708},"Prazosin Hydrochloride",{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1720,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1710,"activeCount":99},[],{"trials":1712,"activeCount":99},[1713],{"nctId":1714,"briefTitle":1715,"status":107,"phases":1716,"primaryCompletion":341,"completion":341,"start":1717,"enrollment":406,"conditions":1718,"interventions":1719},"NCT01999530","The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study",[87],"2013-11",[813],[1707],{"trials":1721,"activeCount":99},[],{"trials":1723,"activeCount":99},[],{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[],{"intervention":1729,"totalTrials":136,"cells":1730},"Bupropion SR",{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1744,"PHASE3":1746,"PHASE4":1748,"NA":1750},{"trials":1732,"activeCount":99},[],{"trials":1734,"activeCount":99},[1735],{"nctId":1736,"briefTitle":1737,"status":107,"phases":1738,"completion":1739,"start":1740,"enrollment":698,"conditions":1741,"interventions":1743},"NCT00133757","Use of Pharmacotherapy to Reduce Cue-responsiveness in Smokers",[87],"2006-05","2005-06",[27,1742],"Tobacco Dependence",[1729],{"trials":1745,"activeCount":99},[],{"trials":1747,"activeCount":99},[],{"trials":1749,"activeCount":99},[],{"trials":1751,"activeCount":99},[],{"intervention":1753,"totalTrials":136,"cells":1754},"alcoholic beverage",{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1769,"PHASE3":1771,"PHASE4":1773,"NA":1775},{"trials":1756,"activeCount":99},[],{"trials":1758,"activeCount":99},[1759],{"nctId":1760,"briefTitle":1761,"status":107,"phases":1762,"primaryCompletion":109,"completion":109,"start":1763,"enrollment":1764,"conditions":1765,"interventions":1767},"NCT01638364","Dopamine Release in the Human Brain Following Alcohol Administration",[87],"2013-01",8,[1766],"Heavy Drinking",[1753,1768],"non-alcoholic beverage",{"trials":1770,"activeCount":99},[],{"trials":1772,"activeCount":99},[],{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[],{"intervention":1768,"totalTrials":136,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1787,"PHASE3":1789,"PHASE4":1791,"NA":1793},{"trials":1780,"activeCount":99},[],{"trials":1782,"activeCount":99},[1783],{"nctId":1760,"briefTitle":1761,"status":107,"phases":1784,"primaryCompletion":109,"completion":109,"start":1763,"enrollment":1764,"conditions":1785,"interventions":1786},[87],[1766],[1753,1768],{"trials":1788,"activeCount":99},[],{"trials":1790,"activeCount":99},[],{"trials":1792,"activeCount":99},[],{"trials":1794,"activeCount":99},[],{"intervention":1796,"totalTrials":136,"cells":1797},"App4Independence",{"EARLY_PHASE1":1798,"PHASE1":1810,"PHASE2":1812,"PHASE3":1814,"PHASE4":1816,"NA":1818},{"trials":1799,"activeCount":99},[1800],{"nctId":1801,"briefTitle":1802,"status":107,"phases":1803,"primaryCompletion":1804,"completion":1804,"start":1805,"enrollment":1806,"conditions":1807,"interventions":1809},"NCT03649815","Feasibility and Outcomes of a Digital Health Support for the Schizophrenia Spectrum",[86],"2018-05-08","2017-04-18",38,[1808],"Schizophrenia Spectrum and Other Psychotic Disorders",[1796],{"trials":1811,"activeCount":99},[],{"trials":1813,"activeCount":99},[],{"trials":1815,"activeCount":99},[],{"trials":1817,"activeCount":99},[],{"trials":1819,"activeCount":99},[],{"intervention":1205,"totalTrials":136,"cells":1821},{"EARLY_PHASE1":1822,"PHASE1":1828,"PHASE2":1830,"PHASE3":1832,"PHASE4":1834,"NA":1836},{"trials":1823,"activeCount":99},[1824],{"nctId":1197,"briefTitle":1198,"status":107,"phases":1825,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":1202,"conditions":1826,"interventions":1827},[86],[18],[1192,1205],{"trials":1829,"activeCount":99},[],{"trials":1831,"activeCount":99},[],{"trials":1833,"activeCount":99},[],{"trials":1835,"activeCount":99},[],{"trials":1837,"activeCount":99},[],{"intervention":1839,"totalTrials":136,"cells":1840},"Citalopram",{"EARLY_PHASE1":1841,"PHASE1":1855,"PHASE2":1857,"PHASE3":1859,"PHASE4":1861,"NA":1863},{"trials":1842,"activeCount":99},[1843],{"nctId":1844,"briefTitle":1845,"status":107,"phases":1846,"primaryCompletion":1847,"completion":1848,"start":1849,"enrollment":396,"conditions":1850,"interventions":1851},"NCT02269540","A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)",[86],"2018-06","2018-07","2014-10",[18],[1852,1839,1853,1854],"Sertraline","N-acetylcysteine","Existing depression medication treatment",{"trials":1856,"activeCount":99},[],{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[],{"trials":1862,"activeCount":99},[],{"trials":1864,"activeCount":99},[],{"intervention":1853,"totalTrials":136,"cells":1866},{"EARLY_PHASE1":1867,"PHASE1":1873,"PHASE2":1875,"PHASE3":1877,"PHASE4":1879,"NA":1881},{"trials":1868,"activeCount":99},[1869],{"nctId":1844,"briefTitle":1845,"status":107,"phases":1870,"primaryCompletion":1847,"completion":1848,"start":1849,"enrollment":396,"conditions":1871,"interventions":1872},[86],[18],[1852,1839,1853,1854],{"trials":1874,"activeCount":99},[],{"trials":1876,"activeCount":99},[],{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[],{"trials":1882,"activeCount":99},[],{"intervention":1854,"totalTrials":136,"cells":1884},{"EARLY_PHASE1":1885,"PHASE1":1891,"PHASE2":1893,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1886,"activeCount":99},[1887],{"nctId":1844,"briefTitle":1845,"status":107,"phases":1888,"primaryCompletion":1847,"completion":1848,"start":1849,"enrollment":396,"conditions":1889,"interventions":1890},[86],[18],[1852,1839,1853,1854],{"trials":1892,"activeCount":99},[],{"trials":1894,"activeCount":99},[],{"trials":1896,"activeCount":99},[],{"trials":1898,"activeCount":99},[],{"trials":1900,"activeCount":99},[],{"intervention":1902,"totalTrials":136,"cells":1903},"delta 9 tetrahydrocannabinol",{"EARLY_PHASE1":1904,"PHASE1":1917,"PHASE2":1919,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1905,"activeCount":99},[1906],{"nctId":1907,"briefTitle":1908,"status":107,"phases":1909,"primaryCompletion":1910,"completion":1910,"start":1911,"enrollment":1912,"conditions":1913,"interventions":1915},"NCT03106363","Combined Alcohol and Cannabis Effects on Skills of Young Drivers",[86],"2020-01-17","2017-07-04",85,[1914],"Psychomotor Impairment",[1902,1916],"Alcohol",{"trials":1918,"activeCount":99},[],{"trials":1920,"activeCount":99},[],{"trials":1922,"activeCount":99},[],{"trials":1924,"activeCount":99},[],{"trials":1926,"activeCount":99},[],{"intervention":1928,"totalTrials":36,"cells":1929},"Varenicline",{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1934,"PHASE3":1952,"PHASE4":1954,"NA":1986},{"trials":1931,"activeCount":99},[],{"trials":1933,"activeCount":99},[],{"trials":1935,"activeCount":99},[1936,1944],{"nctId":1937,"briefTitle":1938,"status":107,"phases":1939,"primaryCompletion":1940,"completion":1940,"start":1340,"enrollment":1941,"conditions":1942,"interventions":1943},"NCT01934023","Effects of Varenicline on Plasticity in Schizophrenia",[88],"2015-08",24,[15],[1928],{"nctId":1945,"briefTitle":1946,"status":107,"phases":1947,"primaryCompletion":341,"completion":341,"start":1948,"enrollment":1949,"conditions":1950,"interventions":1951},"NCT01093365","Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia",[88],"2010-03",58,[15,24],[1928],{"trials":1953,"activeCount":99},[],{"trials":1955,"activeCount":99},[1956,1966,1977],{"nctId":1957,"briefTitle":1958,"status":107,"phases":1959,"primaryCompletion":1960,"completion":1960,"start":1961,"enrollment":333,"conditions":1962,"interventions":1964},"NCT01286584","Varenicline in Drug Treatment",[90],"2014-09","2011-06",[32,1963],"Alcohol Abuse",[1965],"varenicline",{"nctId":1967,"briefTitle":1968,"status":107,"phases":1969,"primaryCompletion":1970,"completion":1970,"start":1971,"enrollment":1972,"conditions":1973,"interventions":1975},"NCT01023659","Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts",[90],"2011-12","2010-04",893,[35,1974,32],"Smoking",[1976,1965],"bupropion",{"nctId":1978,"briefTitle":1979,"status":107,"phases":1980,"primaryCompletion":1981,"completion":1981,"start":1982,"enrollment":22,"conditions":1983,"interventions":1985},"NCT01850953","Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia",[90],"2015-05","2013-06",[1984,1974,15],"Craving",[1928],{"trials":1987,"activeCount":99},[1988,1998,2004,2014,2022,2031],{"nctId":1989,"briefTitle":1990,"status":107,"phases":1991,"primaryCompletion":1992,"completion":1992,"start":1993,"enrollment":1994,"conditions":1995,"interventions":1996},"NCT02146911","The MATCH (Medication Aids for Tobacco Cessation and Health) Study",[91],"2016-12-31","2014-05-01",968,[35,27],[1997,1928],"Bupropion",{"nctId":1999,"briefTitle":2000,"status":107,"phases":2001,"primaryCompletion":1940,"completion":1940,"start":1476,"enrollment":1764,"conditions":2002,"interventions":2003},"NCT01632189","The Effect of Varenicline on D2\u002FD3 Receptor Binding in Smokers",[91],[27],[1928],{"nctId":2005,"briefTitle":2006,"status":107,"phases":2007,"primaryCompletion":2008,"completion":2008,"start":2009,"enrollment":452,"conditions":2010,"interventions":2013},"NCT03841292","Using Non-invasive Brain Stimulation (tDCS) With Varenicline for Treating Tobacco Dependence",[91],"2022-01-31","2018-10-01",[1742,32,198,35,200,2011,2012],"Molecular Mechanisms of Pharmacological Action","Physiological Effects of Drugs",[1928],{"nctId":2015,"briefTitle":2016,"status":107,"phases":2017,"primaryCompletion":2018,"completion":2018,"start":2019,"enrollment":628,"conditions":2020,"interventions":2021},"NCT00873535","Effect of Varenicline on Reactivity to Smoking and Drinking Cues",[91],"2010-01","2008-10",[1742,1159],[1928],{"nctId":2023,"briefTitle":2024,"status":107,"phases":2025,"primaryCompletion":2026,"completion":2027,"start":2028,"enrollment":698,"conditions":2029,"interventions":2030},"NCT04083144","Deep rTMS and Varenicline for Smoking Cessation",[91],"2022-09-13","2022-12-30","2019-08-22",[35,32],[1928],{"nctId":2032,"briefTitle":2033,"status":107,"phases":2034,"primaryCompletion":2035,"completion":1961,"start":2036,"enrollment":342,"conditions":2037,"interventions":2038},"NCT01093937","Study of Varenicline (Champix) for Smoking Cessation\u002FReduction in Patients With Bipolar Disorder",[91],"2011-02","2009-11",[27],[1965],{"intervention":1244,"totalTrials":1410,"cells":2040},{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2047,"PHASE4":2053,"NA":2069},{"trials":2042,"activeCount":99},[],{"trials":2044,"activeCount":99},[],{"trials":2046,"activeCount":99},[],{"trials":2048,"activeCount":99},[2049],{"nctId":1237,"briefTitle":1238,"status":827,"phases":2050,"primaryCompletion":1240,"completion":1240,"start":1241,"enrollment":25,"conditions":2051,"interventions":2052},[88,89],[35,27],[1244,1226],{"trials":2054,"activeCount":99},[2055,2059],{"nctId":656,"briefTitle":657,"status":107,"phases":2056,"primaryCompletion":659,"completion":660,"start":661,"enrollment":662,"conditions":2057,"interventions":2058},[90],[35,27],[665,621],{"nctId":2060,"briefTitle":2061,"status":107,"phases":2062,"primaryCompletion":2063,"completion":2064,"start":2065,"enrollment":2066,"conditions":2067,"interventions":2068},"NCT04606797","Targeting Mailed Nicotine Patch Distribution Interventions to Rural Regions of Canada",[90],"2022-02-16","2022-10-14","2020-11-23",498,[1595],[1244],{"trials":2070,"activeCount":99},[2071,2080,2089],{"nctId":2072,"briefTitle":2073,"status":107,"phases":2074,"primaryCompletion":2075,"start":2076,"enrollment":263,"conditions":2077,"interventions":2079},"NCT00407277","Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia",[91],"2008-08","2007-02",[1974,27,15,2078,24,29],"Schizophreniform Disorders",[1244],{"nctId":2081,"briefTitle":2082,"status":107,"phases":2083,"primaryCompletion":2084,"completion":2084,"start":2085,"enrollment":2086,"conditions":2087,"interventions":2088},"NCT04534231","Offering Nicotine Patches to All Households in a Municipality With High Smoking Rates",[],"2021-08-30","2020-10-19",123,[1595],[1244],{"nctId":2090,"briefTitle":2091,"status":107,"phases":2092,"primaryCompletion":2028,"completion":2028,"start":2093,"enrollment":2094,"conditions":2095,"interventions":2096},"NCT03097445","Long-term Effectiveness of Mailed Nicotine Replacement Therapy: A 5-year Follow-up",[91],"2017-06-04",1000,[32],[1244],{"intervention":2098,"totalTrials":9,"cells":2099},"nicotine replacement therapy",{"EARLY_PHASE1":2100,"PHASE1":2102,"PHASE2":2104,"PHASE3":2106,"PHASE4":2108,"NA":2118},{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[],{"trials":2105,"activeCount":99},[],{"trials":2107,"activeCount":99},[],{"trials":2109,"activeCount":99},[2110],{"nctId":2111,"briefTitle":2112,"status":107,"phases":2113,"primaryCompletion":1201,"completion":1981,"start":2114,"enrollment":2094,"conditions":2115,"interventions":2116},"NCT01429129","Randomized Controlled Trial of Mailed Nicotine Replacement Therapy to Canadian Smokers",[90],"2012-05",[1974],[2117],"Nicotine replacement therapy",{"trials":2119,"activeCount":99},[2120,2129],{"nctId":2121,"briefTitle":2122,"status":107,"phases":2123,"primaryCompletion":2124,"completion":2125,"start":1260,"enrollment":2126,"conditions":2127,"interventions":2128},"NCT00352781","Stop Smoking Therapy for Ontario Patients",[91],"2009-01","2009-08",1767,[1974],[2098],{"nctId":2130,"briefTitle":2131,"status":107,"phases":2132,"primaryCompletion":2133,"completion":2133,"start":2134,"enrollment":2135,"conditions":2136,"interventions":2137},"NCT00356993","Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP)",[91],"2018-03-30","2005-10",6009,[1974],[2138],"Nicotine Replacement Therapy",{"intervention":1368,"totalTrials":95,"cells":2140},{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2145,"PHASE3":2151,"PHASE4":2153,"NA":2155},{"trials":2142,"activeCount":99},[],{"trials":2144,"activeCount":99},[],{"trials":2146,"activeCount":99},[2147],{"nctId":1360,"briefTitle":1361,"status":107,"phases":2148,"primaryCompletion":1363,"completion":1364,"start":1069,"enrollment":1365,"conditions":2149,"interventions":2150},[87,88],[18,21],[1368,1351],{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[],{"trials":2156,"activeCount":99},[2157],{"nctId":2158,"briefTitle":2159,"status":107,"phases":2160,"primaryCompletion":2161,"completion":2161,"start":2162,"enrollment":2163,"conditions":2164,"interventions":2166},"NCT02955719","CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia",[91],"2020-07-16","2016-03-30",145,[21,2165,870],"Anxiety",[1852,2167],"Venlafaxine",{"intervention":2169,"totalTrials":95,"cells":2170},"Sativex",{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2172,"activeCount":99},[],{"trials":2174,"activeCount":99},[],{"trials":2176,"activeCount":99},[2177],{"nctId":2178,"briefTitle":2179,"status":107,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":2183,"conditions":2184,"interventions":2186},"NCT01747850","Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence",[88],"2015-11","2013-03",45,[2185],"Cannabis Dependence",[2169],{"trials":2188,"activeCount":99},[],{"trials":2190,"activeCount":99},[],{"trials":2192,"activeCount":99},[2193],{"nctId":2194,"briefTitle":2195,"status":107,"phases":2196,"primaryCompletion":1960,"completion":1960,"start":2197,"enrollment":464,"conditions":2198,"interventions":2199},"NCT01748799","Fixed or Self-Titrated Dosages of Sativex on Cannabis Users",[91],"2013-02",[2185],[2169],{"intervention":1997,"totalTrials":95,"cells":2201},{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2206,"PHASE3":2208,"PHASE4":2210,"NA":2216},{"trials":2203,"activeCount":99},[],{"trials":2205,"activeCount":99},[],{"trials":2207,"activeCount":99},[],{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[2212],{"nctId":1967,"briefTitle":1968,"status":107,"phases":2213,"primaryCompletion":1970,"completion":1970,"start":1971,"enrollment":1972,"conditions":2214,"interventions":2215},[90],[35,1974,32],[1976,1965],{"trials":2217,"activeCount":99},[2218],{"nctId":1989,"briefTitle":1990,"status":107,"phases":2219,"primaryCompletion":1992,"completion":1992,"start":1993,"enrollment":1994,"conditions":2220,"interventions":2221},[91],[35,27],[1997,1928],{"intervention":1852,"totalTrials":95,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2230,"PHASE2":2232,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":99},[2226],{"nctId":1844,"briefTitle":1845,"status":107,"phases":2227,"primaryCompletion":1847,"completion":1848,"start":1849,"enrollment":396,"conditions":2228,"interventions":2229},[86],[18],[1852,1839,1853,1854],{"trials":2231,"activeCount":99},[],{"trials":2233,"activeCount":99},[],{"trials":2235,"activeCount":99},[],{"trials":2237,"activeCount":99},[],{"trials":2239,"activeCount":99},[2240],{"nctId":2158,"briefTitle":2159,"status":107,"phases":2241,"primaryCompletion":2161,"completion":2161,"start":2162,"enrollment":2163,"conditions":2242,"interventions":2243},[91],[21,2165,870],[1852,2167],{"intervention":1916,"totalTrials":95,"cells":2245},{"EARLY_PHASE1":2246,"PHASE1":2252,"PHASE2":2254,"PHASE3":2256,"PHASE4":2258,"NA":2260},{"trials":2247,"activeCount":99},[2248],{"nctId":1907,"briefTitle":1908,"status":107,"phases":2249,"primaryCompletion":1910,"completion":1910,"start":1911,"enrollment":1912,"conditions":2250,"interventions":2251},[86],[1914],[1902,1916],{"trials":2253,"activeCount":99},[],{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[],{"trials":2259,"activeCount":99},[],{"trials":2261,"activeCount":99},[2262],{"nctId":2263,"briefTitle":2264,"status":107,"phases":2265,"primaryCompletion":2266,"completion":2266,"start":1112,"enrollment":342,"conditions":2267,"interventions":2268},"NCT02710578","Alcohol Effects on Driving-related Skills of Young Drivers",[91],"2017-07-18",[1914],[1916],{"intervention":1161,"totalTrials":95,"cells":2270},{"EARLY_PHASE1":2271,"PHASE1":2273,"PHASE2":2275,"PHASE3":2277,"PHASE4":2279,"NA":2285},{"trials":2272,"activeCount":99},[],{"trials":2274,"activeCount":99},[],{"trials":2276,"activeCount":99},[],{"trials":2278,"activeCount":99},[],{"trials":2280,"activeCount":99},[2281],{"nctId":1154,"briefTitle":1155,"status":827,"phases":2282,"primaryCompletion":997,"completion":997,"start":1157,"enrollment":95,"conditions":2283,"interventions":2284},[90],[1159],[1161,1141],{"trials":2286,"activeCount":99},[2287],{"nctId":2288,"briefTitle":2289,"status":107,"phases":2290,"completion":2291,"start":2292,"enrollment":698,"conditions":2293,"interventions":2295},"NCT00326807","Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling",[91],"2004-06","2001-06",[2294],"Concurrent Alcohol Dependence and Pathological Gambling",[1161],{"intervention":2297,"totalTrials":136,"cells":2298},"Humalog",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2307,"NA":2309},{"trials":2300,"activeCount":99},[],{"trials":2302,"activeCount":99},[],{"trials":2304,"activeCount":99},[],{"trials":2306,"activeCount":99},[],{"trials":2308,"activeCount":99},[],{"trials":2310,"activeCount":99},[2311],{"nctId":2312,"briefTitle":2313,"status":107,"phases":2314,"primaryCompletion":2315,"completion":2315,"start":2316,"enrollment":1941,"conditions":2317,"interventions":2318},"NCT05571878","Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescents",[91],"2025-05-13","2021-09-01",[18,21],[2297,2319],"Saline nasal spray",{"intervention":2319,"totalTrials":136,"cells":2321},{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2330,"NA":2332},{"trials":2323,"activeCount":99},[],{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"trials":2331,"activeCount":99},[],{"trials":2333,"activeCount":99},[2334],{"nctId":2312,"briefTitle":2313,"status":107,"phases":2335,"primaryCompletion":2315,"completion":2315,"start":2316,"enrollment":1941,"conditions":2336,"interventions":2337},[91],[18,21],[2297,2319],{"intervention":2339,"totalTrials":136,"cells":2340},"Genotype dopamine",{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2347,"PHASE4":2349,"NA":2351},{"trials":2342,"activeCount":99},[],{"trials":2344,"activeCount":99},[],{"trials":2346,"activeCount":99},[],{"trials":2348,"activeCount":99},[],{"trials":2350,"activeCount":99},[],{"trials":2352,"activeCount":99},[2353],{"nctId":2354,"briefTitle":2355,"status":107,"phases":2356,"primaryCompletion":2357,"completion":2357,"start":341,"enrollment":2358,"conditions":2359,"interventions":2361},"NCT02921282","Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms",[],"2019-11-29",26,[2360],"Cigarette Smoking Behavior",[2339,2362],"Genotype cannabinoids",{"intervention":2362,"totalTrials":136,"cells":2364},{"EARLY_PHASE1":2365,"PHASE1":2367,"PHASE2":2369,"PHASE3":2371,"PHASE4":2373,"NA":2375},{"trials":2366,"activeCount":99},[],{"trials":2368,"activeCount":99},[],{"trials":2370,"activeCount":99},[],{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":99},[],{"trials":2376,"activeCount":99},[2377],{"nctId":2354,"briefTitle":2355,"status":107,"phases":2378,"primaryCompletion":2357,"completion":2357,"start":341,"enrollment":2358,"conditions":2379,"interventions":2380},[],[2360],[2339,2362],{"intervention":2382,"totalTrials":136,"cells":2383},"Nicoderm",{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2388,"PHASE3":2390,"PHASE4":2392,"NA":2394},{"trials":2385,"activeCount":99},[],{"trials":2387,"activeCount":99},[],{"trials":2389,"activeCount":99},[],{"trials":2391,"activeCount":99},[],{"trials":2393,"activeCount":99},[],{"trials":2395,"activeCount":99},[2396],{"nctId":2397,"briefTitle":2398,"status":107,"phases":2399,"primaryCompletion":2400,"completion":2401,"start":2402,"enrollment":2403,"conditions":2404,"interventions":2405},"NCT00289653","Smoking While on Transdermal Nicotine Replacement Therapy: Effects on Craving and Cessation",[91],"2006-12","2009-07","2005-09",23,[27],[2382],{"intervention":2407,"totalTrials":136,"cells":2408},"ziprazidone",{"EARLY_PHASE1":2409,"PHASE1":2411,"PHASE2":2413,"PHASE3":2415,"PHASE4":2417,"NA":2419},{"trials":2410,"activeCount":99},[],{"trials":2412,"activeCount":99},[],{"trials":2414,"activeCount":99},[],{"trials":2416,"activeCount":99},[],{"trials":2418,"activeCount":99},[],{"trials":2420,"activeCount":99},[2421],{"nctId":2422,"briefTitle":2423,"status":107,"phases":2424,"primaryCompletion":2425,"completion":1961,"start":2124,"enrollment":33,"conditions":2426,"interventions":2427},"NCT00818298","24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study",[91],"2011-01",[15,24],[2407],{"intervention":2429,"totalTrials":136,"cells":2430},"Tetrabenazine",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2439,"NA":2441},{"trials":2432,"activeCount":99},[],{"trials":2434,"activeCount":99},[],{"trials":2436,"activeCount":99},[],{"trials":2438,"activeCount":99},[],{"trials":2440,"activeCount":99},[],{"trials":2442,"activeCount":99},[2443],{"nctId":2444,"briefTitle":2445,"status":107,"phases":2446,"primaryCompletion":2447,"completion":2447,"start":2448,"enrollment":452,"conditions":2449,"interventions":2450},"NCT00362804","Tetrabenazine for Partial Responders",[91],"2006-01","2002-02",[15,24],[2429],{"intervention":2452,"totalTrials":136,"cells":2453},"Benztropine",{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2460,"PHASE4":2462,"NA":2464},{"trials":2455,"activeCount":99},[],{"trials":2457,"activeCount":99},[],{"trials":2459,"activeCount":99},[],{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":99},[],{"trials":2465,"activeCount":99},[2466],{"nctId":2467,"briefTitle":2468,"status":827,"phases":2469,"primaryCompletion":1970,"completion":1970,"start":2470,"enrollment":95,"conditions":2471,"interventions":2474},"NCT00715377","Anticholinergic Burden in Schizophrenia",[91],"2007-06",[15,24,383,2472,2473],"Delusional Disorder","Psychotic Disorders",[2452],{"intervention":2476,"totalTrials":136,"cells":2477},"Cannabis - Placebo Dose",{"EARLY_PHASE1":2478,"PHASE1":2480,"PHASE2":2482,"PHASE3":2484,"PHASE4":2486,"NA":2488},{"trials":2479,"activeCount":99},[],{"trials":2481,"activeCount":99},[],{"trials":2483,"activeCount":99},[],{"trials":2485,"activeCount":99},[],{"trials":2487,"activeCount":99},[],{"trials":2489,"activeCount":99},[2490],{"nctId":2491,"briefTitle":2492,"status":107,"phases":2493,"primaryCompletion":2494,"completion":2494,"start":2495,"enrollment":2496,"conditions":2497,"interventions":2498},"NCT06595576","Cannabis Edibles and Simulated Driving",[91],"2025-04-04","2024-10-01",52,[588,639],[2476,2499,2500,2501],"Cannabis - Low Dose","Cannabis - Medium Dose","Cannabis - High Dose",{"intervention":2499,"totalTrials":136,"cells":2503},{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2508,"PHASE3":2510,"PHASE4":2512,"NA":2514},{"trials":2505,"activeCount":99},[],{"trials":2507,"activeCount":99},[],{"trials":2509,"activeCount":99},[],{"trials":2511,"activeCount":99},[],{"trials":2513,"activeCount":99},[],{"trials":2515,"activeCount":99},[2516],{"nctId":2491,"briefTitle":2492,"status":107,"phases":2517,"primaryCompletion":2494,"completion":2494,"start":2495,"enrollment":2496,"conditions":2518,"interventions":2519},[91],[588,639],[2476,2499,2500,2501],{"intervention":2500,"totalTrials":136,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2530,"NA":2532},{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[],{"trials":2527,"activeCount":99},[],{"trials":2529,"activeCount":99},[],{"trials":2531,"activeCount":99},[],{"trials":2533,"activeCount":99},[2534],{"nctId":2491,"briefTitle":2492,"status":107,"phases":2535,"primaryCompletion":2494,"completion":2494,"start":2495,"enrollment":2496,"conditions":2536,"interventions":2537},[91],[588,639],[2476,2499,2500,2501],{"intervention":2501,"totalTrials":136,"cells":2539},{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2544,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2541,"activeCount":99},[],{"trials":2543,"activeCount":99},[],{"trials":2545,"activeCount":99},[],{"trials":2547,"activeCount":99},[],{"trials":2549,"activeCount":99},[],{"trials":2551,"activeCount":99},[2552],{"nctId":2491,"briefTitle":2492,"status":107,"phases":2553,"primaryCompletion":2494,"completion":2494,"start":2495,"enrollment":2496,"conditions":2554,"interventions":2555},[91],[588,639],[2476,2499,2500,2501],{"intervention":2557,"totalTrials":136,"cells":2558},"Diazepam",{"EARLY_PHASE1":2559,"PHASE1":2561,"PHASE2":2563,"PHASE3":2565,"PHASE4":2567,"NA":2569},{"trials":2560,"activeCount":99},[],{"trials":2562,"activeCount":99},[],{"trials":2564,"activeCount":99},[],{"trials":2566,"activeCount":99},[],{"trials":2568,"activeCount":99},[],{"trials":2570,"activeCount":99},[2571],{"nctId":2572,"briefTitle":2573,"status":107,"phases":2574,"primaryCompletion":2575,"completion":2576,"start":2577,"enrollment":342,"conditions":2578,"interventions":2580},"NCT04858490","Remote Treatment of Alcohol Withdrawal",[91],"2023-10-16","2023-11-21","2021-09-24",[2579],"Alcohol Withdrawal",[2557],{"intervention":2582,"totalTrials":136,"cells":2583},"2 antipsychotic medications",{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2588,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2585,"activeCount":99},[],{"trials":2587,"activeCount":99},[],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[],{"trials":2595,"activeCount":99},[2596],{"nctId":2597,"briefTitle":2598,"status":107,"phases":2599,"primaryCompletion":380,"start":2600,"enrollment":168,"conditions":2601,"interventions":2602},"NCT00493233","Antipsychotic Polypharmacy in Schizophrenia",[91],"2006-11",[15],[2582,2603],"main antipsychotic medication and placebo",{"intervention":2603,"totalTrials":136,"cells":2605},{"EARLY_PHASE1":2606,"PHASE1":2608,"PHASE2":2610,"PHASE3":2612,"PHASE4":2614,"NA":2616},{"trials":2607,"activeCount":99},[],{"trials":2609,"activeCount":99},[],{"trials":2611,"activeCount":99},[],{"trials":2613,"activeCount":99},[],{"trials":2615,"activeCount":99},[],{"trials":2617,"activeCount":99},[2618],{"nctId":2597,"briefTitle":2598,"status":107,"phases":2619,"primaryCompletion":380,"start":2600,"enrollment":168,"conditions":2620,"interventions":2621},[91],[15],[2582,2603],{"intervention":2623,"totalTrials":136,"cells":2624},"ipratropium bromide 0.03% spray",{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2631,"PHASE4":2633,"NA":2635},{"trials":2626,"activeCount":99},[],{"trials":2628,"activeCount":99},[],{"trials":2630,"activeCount":99},[],{"trials":2632,"activeCount":99},[],{"trials":2634,"activeCount":99},[],{"trials":2636,"activeCount":99},[2637],{"nctId":2638,"briefTitle":2639,"status":107,"phases":2640,"primaryCompletion":2641,"start":2642,"enrollment":11,"conditions":2643,"interventions":2645},"NCT00381589","Treatment of Clozapine-Induced Hypersalivation Ipratropium Bromide",[91],"2008-06","2006-10",[2644],"Hypersalivation",[2623],{"intervention":2647,"totalTrials":136,"cells":2648},"Sarizotan",{"EARLY_PHASE1":2649,"PHASE1":2651,"PHASE2":2653,"PHASE3":2655,"PHASE4":2657,"NA":2659},{"trials":2650,"activeCount":99},[],{"trials":2652,"activeCount":99},[],{"trials":2654,"activeCount":99},[],{"trials":2656,"activeCount":99},[],{"trials":2658,"activeCount":99},[],{"trials":2660,"activeCount":99},[2661],{"nctId":2662,"briefTitle":2663,"status":827,"phases":2664,"primaryCompletion":685,"completion":2665,"start":2666,"enrollment":112,"conditions":2667,"interventions":2669},"NCT00310661","Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia",[91],"2008-03","2004-12",[2668],"Neuroleptic-induced Tardive Dyskinesia",[2647],{"intervention":2671,"totalTrials":136,"cells":2672},"Selegiline + nicotine replacement therapy",{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2679,"PHASE4":2681,"NA":2683},{"trials":2674,"activeCount":99},[],{"trials":2676,"activeCount":99},[],{"trials":2678,"activeCount":99},[],{"trials":2680,"activeCount":99},[],{"trials":2682,"activeCount":99},[],{"trials":2684,"activeCount":99},[2685],{"nctId":2686,"briefTitle":2687,"status":827,"phases":2688,"primaryCompletion":2689,"completion":2689,"start":2690,"enrollment":308,"conditions":2691,"interventions":2692},"NCT00390923","Testing a Full Substitution Therapy Approach As Treatment of Tobacco Dependence",[91],"2008-04","2007-07",[27],[2671],{"intervention":2694,"totalTrials":136,"cells":2695},"Nicotine polacrilex",{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2702,"PHASE4":2704,"NA":2706},{"trials":2697,"activeCount":99},[],{"trials":2699,"activeCount":99},[],{"trials":2701,"activeCount":99},[],{"trials":2703,"activeCount":99},[],{"trials":2705,"activeCount":99},[],{"trials":2707,"activeCount":99},[2708],{"nctId":2709,"briefTitle":2710,"status":827,"phases":2711,"primaryCompletion":2712,"completion":2712,"start":2713,"enrollment":406,"conditions":2714,"interventions":2715},"NCT01465074","Effects of Acute Nicotine Treatment on Neuroplasticity and Memory in Patients With Schizophrenia",[91],"2013-04","2011-11",[15],[2694,2716],"Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum",{"intervention":2716,"totalTrials":136,"cells":2718},{"EARLY_PHASE1":2719,"PHASE1":2721,"PHASE2":2723,"PHASE3":2725,"PHASE4":2727,"NA":2729},{"trials":2720,"activeCount":99},[],{"trials":2722,"activeCount":99},[],{"trials":2724,"activeCount":99},[],{"trials":2726,"activeCount":99},[],{"trials":2728,"activeCount":99},[],{"trials":2730,"activeCount":99},[2731],{"nctId":2709,"briefTitle":2710,"status":827,"phases":2732,"primaryCompletion":2712,"completion":2712,"start":2713,"enrollment":406,"conditions":2733,"interventions":2734},[91],[15],[2694,2716],{"intervention":2736,"totalTrials":136,"cells":2737},"Quetiapine",{"EARLY_PHASE1":2738,"PHASE1":2740,"PHASE2":2742,"PHASE3":2744,"PHASE4":2746,"NA":2748},{"trials":2739,"activeCount":99},[],{"trials":2741,"activeCount":99},[],{"trials":2743,"activeCount":99},[],{"trials":2745,"activeCount":99},[],{"trials":2747,"activeCount":99},[],{"trials":2749,"activeCount":99},[2750],{"nctId":2751,"briefTitle":2752,"status":107,"phases":2753,"primaryCompletion":1982,"completion":1982,"start":2641,"enrollment":354,"conditions":2754,"interventions":2761},"NCT00688818","Quetiapine in Co-Morbid Depressive and Anxiety Disorders",[91],[18,2755,2756,2757,2758,2759,2760],"Dysthymic Disorder","Anxiety Disorders","Generalized Anxiety Disorder","Social Anxiety Disorder","Panic Disorder","Post-traumatic Stress Disorder",[2736],{"intervention":2763,"totalTrials":136,"cells":2764},"Intravenous Ketamine",{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2769,"PHASE3":2771,"PHASE4":2773,"NA":2775},{"trials":2766,"activeCount":99},[],{"trials":2768,"activeCount":99},[],{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"trials":2774,"activeCount":99},[],{"trials":2776,"activeCount":99},[2777],{"nctId":2778,"briefTitle":2779,"status":107,"phases":2780,"primaryCompletion":2781,"completion":2781,"start":2782,"enrollment":464,"conditions":2783,"interventions":2786},"NCT05177146","Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression",[91],"2025-01-10","2022-05-04",[2784,2785],"Bipolar Disorder (BD)","Suicidality",[2763],{"intervention":2788,"totalTrials":136,"cells":2789},"Intranasal Ketamine",{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2794,"PHASE3":2796,"PHASE4":2798,"NA":2800},{"trials":2791,"activeCount":99},[],{"trials":2793,"activeCount":99},[],{"trials":2795,"activeCount":99},[],{"trials":2797,"activeCount":99},[],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[2802],{"nctId":2803,"briefTitle":2804,"status":107,"phases":2805,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":11,"conditions":2808,"interventions":2809},"NCT05137938","Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders)",[91],"2023-07-24","2021-10-25",[21],[2788],{"intervention":2811,"totalTrials":136,"cells":2812},"Corticotropin-Releasing Hormone",{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2817,"PHASE3":2819,"PHASE4":2821,"NA":2823},{"trials":2814,"activeCount":99},[],{"trials":2816,"activeCount":99},[],{"trials":2818,"activeCount":99},[],{"trials":2820,"activeCount":99},[],{"trials":2822,"activeCount":99},[],{"trials":2824,"activeCount":99},[2825],{"nctId":2826,"briefTitle":2827,"status":107,"phases":2828,"primaryCompletion":2829,"completion":2829,"start":1982,"enrollment":1046,"conditions":2830,"interventions":2833},"NCT01984177","Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence",[],"2016-06",[2831,2832,1072],"Cocaine-Related Disorders","Cocaine Addiction",[2811],{"intervention":2835,"totalTrials":136,"cells":2836},"Second Generation Long-Acting Injectable Antipsychotic Medications",{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2843,"PHASE4":2845,"NA":2847},{"trials":2838,"activeCount":99},[],{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":99},[],{"trials":2844,"activeCount":99},[],{"trials":2846,"activeCount":99},[],{"trials":2848,"activeCount":99},[2849],{"nctId":2850,"briefTitle":2851,"status":107,"phases":2852,"primaryCompletion":2853,"completion":2853,"start":2854,"enrollment":1317,"conditions":2855,"interventions":2857},"NCT05473741","Risk of Breakthrough Symptoms With Long-Acting Injectable Medications",[],"2025-10-27","2023-01-11",[15,2856],"Schizophrenia Relapse",[2835],{"intervention":2859,"totalTrials":136,"cells":2860},"delta-9-tetrahydrocannabinol",{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2865,"PHASE3":2867,"PHASE4":2869,"NA":2871},{"trials":2862,"activeCount":99},[],{"trials":2864,"activeCount":99},[],{"trials":2866,"activeCount":99},[],{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[],{"trials":2872,"activeCount":99},[2873],{"nctId":2874,"briefTitle":2875,"status":107,"phases":2876,"primaryCompletion":341,"completion":2877,"start":1341,"enrollment":2878,"conditions":2879,"interventions":2880},"NCT01592409","Cannabis Effects on Driving-related Skills of Young Drivers",[91],"2016-09",99,[1914],[2859],{"intervention":2882,"totalTrials":136,"cells":2883},"escitalopram",{"EARLY_PHASE1":2884,"PHASE1":2886,"PHASE2":2888,"PHASE3":2890,"PHASE4":2892,"NA":2894},{"trials":2885,"activeCount":99},[],{"trials":2887,"activeCount":99},[],{"trials":2889,"activeCount":99},[],{"trials":2891,"activeCount":99},[],{"trials":2893,"activeCount":99},[],{"trials":2895,"activeCount":99},[2896],{"nctId":2897,"briefTitle":2898,"status":107,"phases":2899,"primaryCompletion":1982,"completion":1982,"start":2400,"enrollment":2900,"conditions":2901,"interventions":2902},"NCT00517764","Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression",[91],299,[21],[2882],{"intervention":2904,"totalTrials":136,"cells":2905},"Risperidone\u002FOlanzapine and PET scans",{"EARLY_PHASE1":2906,"PHASE1":2908,"PHASE2":2910,"PHASE3":2912,"PHASE4":2914,"NA":2916},{"trials":2907,"activeCount":99},[],{"trials":2909,"activeCount":99},[],{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"trials":2915,"activeCount":99},[],{"trials":2917,"activeCount":99},[2918],{"nctId":2919,"briefTitle":2920,"status":107,"phases":2921,"primaryCompletion":1940,"completion":1940,"start":971,"enrollment":2183,"conditions":2922,"interventions":2924},"NCT00716755","Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.",[91],[15,24,383,2472,2923],"Psychotic Disorder",[2904],{"intervention":2926,"totalTrials":136,"cells":2927},"Desvenlafaxine",{"EARLY_PHASE1":2928,"PHASE1":2930,"PHASE2":2932,"PHASE3":2934,"PHASE4":2936,"NA":2938},{"trials":2929,"activeCount":99},[],{"trials":2931,"activeCount":99},[],{"trials":2933,"activeCount":99},[],{"trials":2935,"activeCount":99},[],{"trials":2937,"activeCount":99},[],{"trials":2939,"activeCount":99},[2940],{"nctId":2941,"briefTitle":2942,"status":107,"phases":2943,"primaryCompletion":158,"completion":158,"start":1157,"enrollment":342,"conditions":2944,"interventions":2945},"NCT01948895","Desvenlafaxine Monotherapy in Dysthymia",[91],[2755],[2926]]